Caladrius Biosciences
TypePublic
Nasdaq: CLBS
Russell Microcap Index component
IndustryBiopharmaceuticals
HeadquartersBasking Ridge, New Jersey[1],
United States
Key people
David J. Mazzo
(CEO)
Websitecaladrius.com

Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.[2]

Founded in 1980,[3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc,[4] and NeoStem, Inc., it adopted its current name in 2015.[3]

In 2022, Caladrius and Cend Therapeutics merged to form Lisata Therapeutics.[5]

Cardiovascular disease

In 2012 it started a randomized, controlled, double-blind phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for marked reduction in left ventricular function following acute myocardial infarction.[6]

The published study results showed no evidence of benefit from pre-specified endpoints, though there appeared to be evidence suggesting possible dose-related benefit in post-hoc analysis from a subset of patients. [7]

References

  1. ↑ Editorial, Reuters. "CLBS.PH - Caladrius Biosciences Inc Profile | Reuters". www.reuters.comundefined. {{cite web}}: |first1= has generic name (help)
  2. ↑ NeoStem CEO Discusses Adult Stem Cell Therapies, May 14, 2012. Bloomberg Television. 3m35s video. Accessed September 2015.
  3. 1 2 "Caladrius Biosciences - Consensus Indicates Potential 316.7% Upside - DirectorsTalk Interviews". Retrieved 2021-05-03.
  4. ↑ EDGAR Search Results – Neostem, EDGAR
  5. ↑ Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics, September 15, 2022
  6. ↑ NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)
  7. ↑ Arshad A. Quyyumi (2017). "PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI". Circulation Research. 120 (2): 324–331. doi:10.1161/CIRCRESAHA.115.308165. PMC 5903285. PMID 27821724.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.